Profile data is unavailable for this security.
About the company
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
- Revenue in USD (TTM)255.72k
- Net income in USD-4.40m
- Incorporated2011
- Employees0.00
- LocationEndonovo Therapeutics Inc6320 Canoga Avenue, 15Th FloorWOODLAND HILLS 91367United StatesUSA
- Phone+1 (800) 489-4774
- Fax+1 (818) 230-9899
- Websitehttps://endonovo.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Propanc Biopharma Inc | 0.00 | -2.46m | 159.58k | 1.00 | -- | -- | -- | -- | -0.3033 | -0.3033 | 0.00 | -0.0337 | 0.00 | -- | -- | -- | -2,440.90 | -4,945.87 | -- | -- | -- | -- | -- | -- | -- | -1.70 | -- | -- | -- | -- | -17.63 | -- | -- | -- |
ContraFect Corp | 0.00 | -24.14m | 161.64k | 23.00 | -- | -- | -- | -- | -19.25 | -19.25 | 0.00 | -0.538 | 0.00 | -- | -- | 0.00 | -150.12 | -74.17 | -- | -94.04 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -221.24 | -- | -- | -- |
Acorda Therapeutics Inc | 115.66m | -263.43m | 186.31k | 102.00 | -- | -- | -- | 0.0016 | -212.10 | -212.10 | 93.13 | -149.56 | 0.5068 | 1.14 | 12.59 | 1,133,961.00 | -115.42 | -26.62 | -266.35 | -31.97 | 86.38 | 78.22 | -227.75 | -111.91 | 0.1533 | -0.692 | 33.57 | -- | -0.7869 | -24.24 | -283.60 | -- | -62.13 | -- |
Athersys Inc | 80.00k | -37.51m | 191.33k | 24.00 | -- | -- | -- | 2.39 | -2.03 | -2.03 | 0.004 | -1.36 | 0.0037 | -- | 0.2424 | 3,333.33 | -174.57 | -120.93 | -- | -206.72 | -- | -- | -46,883.75 | -727.72 | -- | -- | -- | -- | -3.43 | 7.51 | 16.58 | -- | 6.85 | -- |
CNBX Pharmaceuticals Inc | 540.25k | -1.23m | 214.67k | 2.00 | -- | -- | -- | 0.3974 | -0.0583 | -0.0583 | 0.0237 | -0.0758 | 1.73 | -- | -- | 270,125.00 | -393.70 | -73.32 | -- | -99.80 | 6.37 | -- | -228.08 | -3,970.88 | -- | -1.37 | -- | -- | -- | 111.90 | 0.3497 | -- | -- | -- |
Endonovo Therapeutics Inc | 255.72k | -4.40m | 314.45k | 0.00 | -- | -- | -- | 1.23 | -0.0652 | -0.0652 | 0.0003 | -0.072 | 0.2256 | -- | -- | -- | -388.54 | -303.26 | -- | -- | 96.21 | 74.38 | -1,722.26 | -5,956.27 | -- | -1.38 | -- | -- | 85.15 | -- | -495.02 | -- | -- | -- |
Health Advance Inc | -100.00bn | -100.00bn | 390.49k | 3.00 | -- | 0.0993 | -- | -- | -- | -- | -- | 0.0212 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0356 | -- | 100.00 | -- | -21.75 | -- | -- | -- |
eFFECTOR Therapeutics Inc | 0.00 | -34.63m | 392.82k | 14.00 | -- | 0.394 | -- | -- | -13.31 | -13.31 | 0.00 | 0.2119 | 0.00 | -- | -- | 0.00 | -141.18 | -- | -- | -- | -- | -- | -- | -- | -- | -17.12 | 0.9581 | -- | -100.00 | -- | -58.00 | -- | -- | -- |
NovAccess Global Inc | 0.00 | -1.74m | 446.03k | 1.00 | -- | -- | -- | -- | -0.1193 | -0.1193 | 0.00 | -0.2246 | 0.00 | -- | -- | 0.00 | -1,836.30 | -2,185.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -177.93 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Family CFO, Inc.as of 31 Mar 2024 | 0.00 | 0.00% |